Clinical trials: Neuroprotection
Drug Drug Interaction (DDI)
A Study Evaluating the Potential of BMS-984923 to Alter the Systemic Exposure of Three Orally Administered Probe Substrates
The goal of this study is to learn if the investigational drug, BMS-984923 will impact the exposure and clearance of other medications when given together.
- Trial name
- NCT06632990
- Testing
- BMS-984923, Midazolam, Caffeine
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Allyx Therapeutics
Carotid Stenosis, Carotid Artery Diseases
The ENROUTE Transcarotid Neuroprotection System (ENROUTE Transcarotid NPS) DW-MRI Study
The goal of this study is to evaluate the incidence of post procedure DW-MRI lesions (relative to baseline) and debris captured in the ENROUTE Transcarotid NPS inline filter during a transcarotid stenting procedure.
- Conditions
- Carotid Stenosis, Carotid Artery Diseases, Carotid Atherosclerosis, Carotid Artery Plaque
- Trial name
- DW-MRI OUS (NCT03985774)
- Testing
- Transcarotid revascularization
- Where
- 3 sites in Belgium, Germany and 1 more
- Volunteers
- 31 people
- Sponsor
- Silk Road Medical
Amyotrophic Lateral Sclerosis
Evaluation the Efficacy and Safety of Mutiple Lenzumestrocel (Neuronata-R® Inj.) Treatment in Patients With ALS
ALSUMMIT is a double-blind, randomized, placebo-controlled, multi-center, parallel, phase III clinical trial to evaluate and confirm the efficacy and long-term safety of repeated Lenzumestrocel (Neuronata-R® inj.) treatment.
- Trial name
- ALSummit (NCT04745299)
- Testing
- Lenzumestrocel, Riluzole
- Where
- 5 sites in South Korea
- Volunteers
- 123 people
- Sponsor
- Corestemchemon, Inc.
Stroke
Evaluating Neuroprotection in Aneurysm Coiling Therapy
This is a randomized, double-blind, placebo-controlled, single-dose, design investigating the safety, tolerability and efficacy of NA-1, a peptide designed to reduce ischemic brain damage.
- Trial name
- ENACT (NCT00728182)
- Testing
- NA-1
- Where
- 14 sites in United States, Canada
- Volunteers
- 185 people
- Sponsor
- NoNO Inc.
Cardiac Arrest
Antioxidant and NMDA Receptor Blocker Wins Anoxic Brain Damage of KorEa OHCA Patients
This study aims to investigate the efficacy and safety of Neu2000KWL, a neuroprotectant, in patients resuscitated from out-of-hospital cardiac arrest and receiving therapeutic hypothermia.
- Trial name
- AWAKE (NCT03651557)
- Testing
- Neu2000KWL High-dose group, Neu2000KWL Low-dose group
- Where
- 6 sites in South Korea
- Volunteers
- 150 people
- Sponsor
- GNT Pharma
Primary Open-Angle Glaucoma (POAG)
Efficacy and Safety of Different Dosages of Mexidol® in Patients With Primary Open-angle Glaucoma (POAG)
The present trial is planned to investigate and identify the best dosage of investigational drugs with respect to the treatment of open-angle glaucoma.
- Trial name
- NCT06903156
- Testing
- Mexidol
- Where
- 7 sites in Russia
- Volunteers
- 102 people
- Sponsor
- Pharmasoft
Primary Open-Angle Glaucoma (POAG)
MEXIDOL® Sequential Therapy of Patients With Primary Open-angle Glaucoma (POAG)
Hypothesis: The use of neurocytoprotectors helps restore the functional activity of mitochondria, improve the nervous activity of the retina and optic nerve, and stabilize the glaucomatous process.
- Trial name
- NCT06437639
- Testing
- Mexidol
- Where
- Russia
- Volunteers
- 80 people
- Sponsor
- Pharmasoft
Carotid Artery Stenosis
CGUARDIANS III IDE Pivotal Trial
This is a prospective, multi-center, single-arm, pivotal study. The objective of this study is to evaluate the safety and efficacy of the SwitchGuard NPS in providing cerebral embolic protection during Transcarotid Artery…
- Trial name
- NCT07277296
- Testing
- SwitchGuardTM NPS
- Volunteers
- 103 people
- Sponsor
- InspireMD
Healthy Aging, Dietary Supplement
Effect of BrainPhyt, a Microalgae Based Ingredient on Cognitive Function in Healthy Older Subjects
In developed countries, the acceleration of the general population ageing has been widely described for decades, involving changes in public health policies.
- Conditions
- Healthy Aging, Dietary Supplement, Fucoxanthin, Cognitive Impairment
- Trial name
- PHAEOSOL-THREE (NCT04832412)
- Testing
- BrainPhyt, 100 % Maltodextrin
- Where
- Ireland
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Microphyt
Acute Ischemic Stroke
Hybernia Medical Post-Mechanical Thrombectomy Cerebral Cooling in Stroke
Reducing the temperature of tissue or organs (hypothermia) produces a protective state, through multiple molecular mechanisms, against adverse effects that arise from disrupted organ blood flow, e.g.
- Trial name
- Post-MECC (NCT06634303)
- Testing
- Brain cooling
- Where
- Spain
- Volunteers
- 8 people
- Sponsor
- Hybernia Medical